Publication: Flow cytometric analysis of DNA ploidy and S-phase fraction of Stage IIIB cervical carcinoma
Issued Date
2004-08-02
Resource Type
ISSN
03922936
Other identifier(s)
2-s2.0-3242724338
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Gynaecological Oncology. Vol.25, No.4 (2004), 428-430
Suggested Citation
S. Wilailak, M. Rochanawutanon, S. Srisupundit, A. Aumkhyan, K. Pattanapanyasat Flow cytometric analysis of DNA ploidy and S-phase fraction of Stage IIIB cervical carcinoma. European Journal of Gynaecological Oncology. Vol.25, No.4 (2004), 428-430. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/21583
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Flow cytometric analysis of DNA ploidy and S-phase fraction of Stage IIIB cervical carcinoma
Other Contributor(s)
Abstract
Objectives: To evaluate the role of flow cytometry-measured DNA ploidy and S-phase fraction as survival prognostic indicators in women with FIGO Stage IIIB squamous cell carcinoma of cervix. Methods: We retrospectively reviewed the medical and pathological records of women with Stage IIIB squamous cell cervical carcinoma treated between 1993 and 1996. Flow cytometric analysis of DNA ploidy and S-phase fraction was performed by the modified Hedley technique using paraffin-embedded tissue. Survival was calculated using the Kaplan-Meier life-table analysis. Results: Of the 75 cases, 66 were analyzable. Diploid tumors were found in 73%. The mean S-phase fraction was 14% (SD = 5.4). The overall 5-year survival rate was 60%. The survival of patients with aneuploidy tumors was significantly worse than that of the diploid tumors (p = 0.001). The survival of the patients who had S-phase fraction > 12% was significantly worse than those who had S-phase fraction ≤ 12% (p = 0.04). Conclusions: In this homogeneous study population, we found that aneuploidy and S-phase fraction > 12% correlated with poor survival. Identifying this poor prognostic group would be of benefit in considering additional treatment for a better outcome.